CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) shares dropped 0.7% on Friday . The company traded as low as $1.45 and last traded at $1.48. Approximately 2,369 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 39,923 shares. The stock had previously closed at $1.49.
Wall Street Analyst Weigh In
Separately, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 price objective on shares of CytoMed Therapeutics in a research note on Tuesday, June 11th.
Read Our Latest Research Report on GDTC
CytoMed Therapeutics Trading Down 0.7 %
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.
Featured Stories
- Five stocks we like better than CytoMed Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- 3 Monster Growth Stocks to Buy Now
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.